Alkabbani, W. ., Shah, B. R., Zongo, A. ., Eurich, D. T., Alsabbagh, M. W., & Gamble, J. M. (2023). Post-initiation predictors of discontinuation of the sodium-glucose cotransporter-2 inhibitors: A comparative cohort study from the United Kingdom. Diabetes Obes Metab. http://doi.org/10.1111/dom.15241
SGLT2 inhibitor
van Hulten, V. ., Driessen, J. H. M., Starup-Linde, J. K., Al-Mashhadi, Z. K., Viggers, R. ., Klungel, O. H., … van den Bergh, J. P. (2023). The associations of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as add-on to metformin with fracture risk in patients with type 2 diabetes mellitus. Diabetes Obes Metab. http://doi.org/10.1111/dom.15220
Birkeland, K. I., Bodegard, J. ., Banerjee, A. ., Kim, D. J., Norhammar, A. ., Eriksson, J. W., … Kadowaki, T. . (2021). Lower cardiorenal risk with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study. Diabetes Obes Metab, 23, 75–85. http://doi.org/10.1111/dom.14189
Idris, I. ., Zhang, R. ., Mamza, J. B., Ford, M. ., Morris, T. ., Banerjee, A. ., & Khunti, K. . (2022). Significant reduction in chronic kidney disease progression with sodium-glucose cotransporter-2 inhibitors compared to dipeptidyl peptidase-4 inhibitors in adults with type 2 diabetes in a UK clinical setting. Diabetes Obes Metab. http://doi.org/10.1111/dom.14799